Abstract
Aprepitant (EMEND) is the first commercially available drug from a new class of agents, the Substance P/neurokinin NK-1 receptor antagonists. Aprepitant is indicated for prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV) associated with highly emetogenic chemotherapy in adults. Its ability to antagonize the effects of Substance P has lead to greater understanding of the pathophysiology of nausea and vomiting. Its broad range of activity against a wide variety of central and peripheral emetogenic stimuli make it potentially useful in non-chemotherapy related nausea and vomiting.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 31-39 |
| Number of pages | 9 |
| Journal | Journal of Pain and Palliative Care Pharmacotherapy |
| Volume | 19 |
| Issue number | 3 |
| DOIs | |
| State | Published - 2005 |
Keywords
- Antagonist
- Aprepitant
- Nausea
- Neurokinin
- Review
- Substance P
- Vomiting
ASJC Scopus subject areas
- Anesthesiology and Pain Medicine
- Pharmacology (medical)